Skip to Content

Merck & Co Inc MRK

Morningstar Rating
$129.48 +0.11 (0.09%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Led by Keytruda, Merck Holds Solid Growth Potential Over the Next Five Years

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the Organon business in June 2021, the remaining portfolio at Merck holds a higher percentage of drugs with strong patent protection. On the pipeline front, after several years of only moderate research and development productivity, Merck's drug development strategy is yielding important new drugs.

Price vs Fair Value

MRK is trading within a range we consider fairly valued.
Price
$129.48
Fair Value
$218.00
Uncertainty
Medium
1-Star Price
$792.00
5-Star Price
$74.00
Economic Moat
Rtzf
Capital Allocation
Jgqpsbts

Bulls Say, Bears Say

Bulls

Keytruda looks best positioned in the immuno-oncology landscape, buoyed by a first-mover advantage in the important indication of first-line non-small cell lung cancer.

Bears

Outside of immuno oncology, Merck needs to increase the number of late-stage pipeline drugs.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MRK is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$129.37
Day Range
$128.65129.87
52-Week Range
$99.14133.10
Bid/Ask
$128.60 / $130.77
Market Cap
$327.95 Bil
Volume/Avg
7.3 Mil / 8.2 Mil

Key Statistics

Price/Earnings (Normalized)
59.67
Price/Sales
5.37
Dividend Yield (Trailing)
2.32%
Dividend Yield (Forward)
2.38%
Total Yield
2.72%

Company Profile

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
72,000

Competitors

Valuation

Metric
MRK
LLY
PFE
Price/Earnings (Normalized)
59.6793.9419.21
Price/Book Value
8.1265.161.69
Price/Sales
5.3722.092.82
Price/Cash Flow
18.8891.7918.12
Price/Earnings
MRK
LLY
PFE

Financial Strength

Metric
MRK
LLY
PFE
Quick Ratio
0.680.680.67
Current Ratio
1.251.351.05
Interest Coverage
3.9714.11−0.26
Quick Ratio
MRK
LLY
PFE

Profitability

Metric
MRK
LLY
PFE
Return on Assets (Normalized)
5.22%11.20%3.77%
Return on Equity (Normalized)
13.56%57.69%8.51%
Return on Invested Capital (Normalized)
8.29%20.65%5.75%
Return on Assets
MRK
LLY
PFE
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
YhhwktgjdvGjkl$834.9 Bil
Johnson & Johnson
JNJ
VlgfrhydZqjw$350.3 Bil
AbbVie Inc
ABBV
ZnwkdwxdQhvz$297.7 Bil
AstraZeneca PLC ADR
AZN
ShmzvssbzrVkkz$247.3 Bil
Roche Holding AG ADR
RHHBY
PsffbmhbyKcyyt$223.9 Bil
Novartis AG ADR
NVS
FfnywpnvBnmb$216.8 Bil
Amgen Inc
AMGN
TyqrwcvpgXdd$160.2 Bil
Pfizer Inc
PFE
NqmtkmtvBzy$156.0 Bil
Sanofi SA ADR
SNY
XctlbfjmFpkxl$116.1 Bil

Sponsor Center